A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism

Coniglio, Susan J.; Lewis, Jeffery D.; Lang, Claudia; Burns, Thomas G.; Subhani-Siddique, Rabia; Weintraub, Alan; Schub, Howard S.; Holden, E.

doi:10.1067/mpd.2001.112474

Cited by 58 publications

(41 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, multiple receptor agonists within this family are currently approved drugs utilized for diagnostic or therapeutic purposes, or under active clinical investigation for the treatment of specific human disorders. Hence, secretin may be used clinically for assessment of pancreatic function or for analysis of gastrin secretion in subjects with gastrinomas, and secretin-based therapies remain under investigation for the treatment of human diseases such as autism (Coniglio et al, 2001). GHRH is administered as a diagnostic challenge for the assessment of pituitary growth hormone reserve, and GHRH analogs, as well as GHRH receptor ligands, are under active investigation for conditions characterized by relative or absolute growth hormone deficiency (Gaylinn, 1999).…”

Section: Discussionmentioning

confidence: 99%

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

et al. 2003

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

et al. 2003

View full text Add to dashboard Cite

“…Subsequent controlled studies in autism (Dunn-Geier et al, 2000;Lightdale et al, 2001;Owley et al, 2001), have either failed to confirm the Horvath study, or have demonstrated a modest trend toward behavioral improvements (Coniglio et al, 2001). Secretin has also been described as being potentially therapeutic for disorders distantly related to autism such as schizophrenia (Sheitman et al, 2004).…”

Section: Secretinmentioning

confidence: 99%

Class II G Protein-Coupled Receptors and Their Ligands in Neuronal Function and Protection

Martin

Maturana²,

Brenneman

et al. 2005

NMM

View full text Add to dashboard Cite

G protein-coupled receptors (GPCRs) play pivotal roles in regulating the function and plasticity of neuronal circuits in the nervous system. Among the myriad of GPCRs expressed in neural cells, class II GPCRs which couples predominantly to the Gs-adenylate cyclase-cAMP signaling pathway, have recently received considerable attention for their involvement in regulating neuronal survival. Neuropeptides that activate class II GPCRs include secretin, glucagon-like peptides (GLP-1 and GLP-2), growth hormone-releasing hormone (GHRH), pituitary adenylate cyclase activating peptide (PACAP), corticotropin-releasing hormone (CRH), vasoactive intestinal peptide (VIP), parathyroid hormone (PTH), and calcitonin-related peptides. Studies of patients and animal and cell culture models, have revealed possible roles for class II GPCRs signaling in the pathogenesis of several prominent neurodegenerative conditions including stroke, Alzheimer's, Parkinson's, and Huntington's diseases. Many of the peptides that activate class II GPCRs promote neuron survival by increasing the resistance of the cells to oxidative, metabolic, and excitotoxic injury. A better understanding of the cellular and molecular mechanisms by which class II GPCRs signaling modulates neuronal survival and plasticity will likely lead to novel therapeutic interventions for neurodegenerative disorders.

show abstract

“…18 Of the 8 studies that evaluated the impact of secretin in the treatment of ASDs, 1 study 15 was a repeated-dose intervention study. Two studies used synthetic human secretin, 11,12 3 used porcine secretin, 14,16,17 and 1 used biological secretin; 13 1 report did not specify the type of secretin used. 18 All of the studies evaluated only shortterm outcomes and had follow-up periods that ranged from 3 to 12 weeks.…”

Section: Data Synthesismentioning

confidence: 99%

“…Figure 1 shows the flow of articles retrieved for the review. Among 4120 ar- 18 We assessed 2 trials as being of good quality, 14,15 5 as being of fair quality, [11][12][13][16][17] and the case series as being of poor quality. 18 Of the 8 studies that evaluated the impact of secretin in the treatment of ASDs, 1 study 15 was a repeated-dose intervention study.…”

Section: Data Synthesismentioning

confidence: 99%

A Systematic Review of Secretin for Children With Autism Spectrum Disorders

2011

View full text Add to dashboard Cite

CONTEXT: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Secretin is 1 of many medical treatments studied for treating the symptoms of ASDs, but there is currently no consensus regarding which interventions are most effective. OBJECTIVE: To systematically review evidence regarding the use of secretin in children with ASDs who are aged 12 years and younger. METHODS: We searched the Medline, PsycINFO, and ERIC (Education Resources Information Center) databases from 2000 to May 2010 and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria. RESULTS: Evidence from 7 randomized controlled trials supports a lack of effectiveness of secretin for the treatment of ASD symptoms including language and communication impairment, symptom severity, and cognitive and social skill deficits. No studies have resulted in significantly greater improvements in measures of language, cognition, or autistic symptoms when compared with placebo; study authors who reported improvement over time did so equally for both the intervention and placebo groups. CONCLUSIONS: Secretin has been studied extensively in multiple randomized controlled trials, and there is clear evidence that it lacks benefit. The studies of secretin included in this review uniformly point to a lack of significant impact of secretin in the treatment of ASD symptoms. Given the high strength of evidence for a lack of effectiveness, secretin as a treatment approach for ASDs warrants no further study.

show abstract

A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism

Cited by 58 publications

References 4 publications

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

Class II G Protein-Coupled Receptors and Their Ligands in Neuronal Function and Protection

A Systematic Review of Secretin for Children With Autism Spectrum Disorders

Contact Info

Product

Resources

About